Condyloma Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2017-2021 and Forecast 2022-2028

$ PRICE - $ 3,000.00$ 8,900.00

Condyloma Market: By Treatment (Prescription Drugs and Surgeries), End User (Hospitals, Retail Pharmacies, and Online Pharmacies), Geographical Location (North America, Europe, Asia-Pacific, Latin America, Middle East, And Africa), and Forecast To 2028

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail
SKU: N/A Categories: ,

Report

Description

Condyloma Market Size was valued at USD 1,739.6 Million in 2021 and is poised to grow at a significant CAGR of 5.1% over the forecast period of 2022-2028. Anogenital warts spurred on by the human papillomavirus (HPV) are referred to as condyloma acuminate and can affect both the male and female populations. Anogenital warts are most frequently carried on by HPV strains 6 and 11. Warts can develop anywhere near the vagina, cervix (in females), and scrotum, penis, groin, or thighs (in males). A double-stranded DNA virus called HPV is typically transmitted through intercourse. Condyloma acuminata susceptibility is influenced by one’s age, way of life, and sexual habits. Topical treatments include imiquimod cream, sinecatechins ointment, and solutions and creams containing podophyllotoxin. Other viable therapies include cryotherapy, trichloroacetic acid solution, and several surgical techniques. Following topical therapies, Condyloma acuminata has a possibility of returning. The only therapy with clearance rates close to 100% is surgical excision. Patients should be given advice on available treatments, the value of follow-up visits, and safe sex procedures. With 9 to 13 percent of the world’s population afflicted, HPV is the most prevalent sexually transmitted illness. Most often, patients between the ages of 20 and 39 are impacted. Thus, with high prevalence, primarily in the young generation, the condyloma treatment market is predicted to grow in the presumption period. There are several identified risk factors for HPV infection. The likelihood of contracting an infection rises with more past sexual partners, a history of gonorrhea and chlamydia infections, smoking, and HIV infection. With around 10 million cigarettes sold worldwide and 36.9 million people living with HIV (including 1.8 million children), the chances of condyloma morbidity are to increase in the future, thus giving the thrust for the condyloma market growth. The occurrence of condyloma acuminata is challenging to predict since anogenital warts are not a disease that must be reported. However, according to current estimates, there are 1.1 to 1.2 incidences of anogenital warts per 1000 people per year in the United States. Further, there are international level efforts by the World Health Organization to educate the population through an authoritarian level awareness campaign and eliminate sexually transmitted diseases by providing health care facilities and funds to the governments worldwide, which will drive the condyloma treatment market to flourish in the prognosticate span of the report. The major restrain for the condyloma market is the nonreporting of the disease. The disease prevalence is much higher than reported as this disease is typically nonlethal many infected patients never report it.

Key Developments:

March 2021, Verrica signed a License Agreement with Torii Pharmaceutical Co. Ltd. granting Torii an exclusive license to develop and commercialize Verrica’s product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102.

In October 2018, Novan entered partnership with Health Decisions, a specialist Contract Research Organization (CRO), and announced clinical trial Phase II data for the treatment of external genital warts (EGW).

Condyloma Market

MARKET SUMMARY
-
5.1%
  • Study Period– 2022 – 2028
  • Base Year– 2021
  • CAGR– 5.1%
  • Largest Market– Asia Pacific
  • Fastest Growing Market– North America

Condyloma Market

  • The global condyloma market report gives a comprehensive outlook across the globe with particular emphasis on key regions such as North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa.
  • The report on the global condyloma market gives historical, current, and future market sizes on the basis of treatment, end user, and geography.
Key Players
  • Perrigo Company plc
  • Novartis AG
  • Merck & Co. Inc.
  • Emblation Ltd.
  • Verrica Pharmaceuticals
Condyloma Market Dynamics

The prevalence of diseases caused by the Human Papilloma Virus is the most common kind of sexually transmitted disease worldwide. History of gonorrhea, Smoking, multiple sexual partners, and the presence of HIV infection is the main cause of the disease to spread worldwide. Thus, with the increase in etiology of the disease in modern society, the condyloma treatment demand either in pharmacological or surgical methods or in another advanced technological way (cryotherapy) is about to multiply. Thus, the condyloma market report by Precision Business Insights picturizes the market growth in the forecast period at a constant CAGR of 5.1%.


North-America Got Significant Share

Condyloma Market

Due to favorable reimbursement conditions, increased pharmaceutical industry investment in therapy innovation, and higher reporting of the disease occurrence, North America now holds a relatively large market share. Due to favorable government legislation and increased public knowledge of STD treatments, Europe is predicted to have the second-largest market for condyloma acuminata therapy. As the etiology of the disease is associated with the modern lifestyle, developed countries are susceptible to higher disease prevalence. Also, the disease prevalence is associated with unsafe sexual practices which is the prime cause of STDs in developing and underdeveloped countries. Thus, the Asia-Pacific and African countries did also come under the susceptibility radar. Due to its quickly developing healthcare infrastructure amid rising STD incidence, and awareness about the treatments Asia-Pacific and Africa are predicted to have the greatest market share for condyloma acuminata treatments during the subsequent years.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Features of the Report

  • The condyloma market report provides granular level information about the market size, regional market share, historic market (2017-2021), and forecast (2022-2028)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and startup details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
  • The report analyses the impact of the socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
Condyloma Market Segmentation


Location

GEOGRAPHY

Frequently Asked Questions

The denture market is projected to expand at a CAGR of 5.1% during the forecast period

Perrigo Company plc, Novartis AG, Merck & Co. Inc., Emblation Ltd., Verrica Pharmaceuticals, Novan, Inc., GlaxoSmithKline plc., Pfizer Inc., Mylan N.V.

North America is the fastest-growing region for the condyloma market


Report

Table Of Content

1. Executive Summary
2. Global Condyloma Market Introduction
2.1. Global Condyloma Market – Taxonomy
2.2. Global Condyloma Market –Definitions
2.2.1. By Treatment
2.2.2. By End User
2.2.3. By Region
3. Global Condyloma Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Condyloma Market Dynamic Factors – Impact Analysis
3.6. Global Condyloma Market – Competition Landscape
3.7. Epidemiology
4. Global Condyloma Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028
4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Global Condyloma Market, By Treatment, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.1. Prescription Drugs
5.1.1. Imiquimod
5.1.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
5.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.1.3. Market Opportunity Analysis
5.1.2. Podophyllin and Podofilox
5.1.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
5.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.2.3. Market Opportunity Analysis
5.1.3. Trichloroacetic Acid
5.1.3.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
5.1.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3.3. Market Opportunity Analysis
5.1.4. Sinecatechins
5.1.4.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
5.1.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.4.3. Market Opportunity Analysis
5.1.5. Others
5.1.5.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
5.1.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.5.3. Market Opportunity Analysis
5.2. Surgery
5.2.1. Cryotherapy
5.2.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
5.2.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.1.3. Market Opportunity Analysis
5.2.2. Electrocautery
5.2.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
5.2.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.2.3. Market Opportunity Analysis
5.2.3. Surgical Excision
5.2.3.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
5.2.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3.3. Market Opportunity Analysis
5.2.4. Laser Treatments
5.2.4.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
5.2.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.4.3. Market Opportunity Analysis
5.2.5. Others
5.2.5.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
5.2.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.5.3. Market Opportunity Analysis
6. Global Condyloma Market Forecast, By End User, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.1. Hospitals
6.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Retail Pharmacies
6.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Online Pharmacies
6.3.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
7. Global Condyloma Market Forecast, By Region, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.1. North America
7.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Europe
7.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Asia-Pacific
7.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Latin America
7.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
7.5. Middle East and Africa
7.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.5.3. Market Opportunity Analysis
7.6. Global Condyloma Market – Opportunity Analysis Index, By Treatment, By End User, and Region, 2022 – 2028
8. North America Condyloma Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.1. Treatment Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
8.1.1. Prescription Drugs
8.1.1.1. Imiquimod
8.1.1.2. Podophyllin and Podofilox
8.1.1.3. Trichloroacetic Acid
8.1.1.4. Sinecatechins
8.1.1.5. Others
8.1.2. Surgery
8.1.2.1. Cryotherapy
8.1.2.2. Electrocautery
8.1.2.3. Surgical Excision
8.1.2.4. Laser Treatments
8.1.2.5. Others
8.2. End User Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
8.2.1. Hospitals
8.2.2. Retail Pharmacies
8.2.3. Online Pharmacies
8.3. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
8.3.1. USA
8.3.2. Canada
8.4. North America Condyloma Market – Opportunity Analysis Index, By Treatment, By End User, and Country, 2022 – 2028
8.5. North America Condyloma Market Dynamics – Trends
9. Europe Condyloma Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
9.1. Treatment Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1. Prescription Drugs
9.1.1.1. Imiquimod
9.1.1.2. Podophyllin and Podofilox
9.1.1.3. Trichloroacetic Acid
9.1.1.4. Sinecatechins
9.1.1.5. Others
9.1.2. Surgery
9.1.2.1. Cryotherapy
9.1.2.2. Electrocautery
9.1.2.3. Surgical Excision
9.1.2.4. Laser Treatments
9.1.2.5. Others
9.2. End User Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.2.1. Hospitals
9.2.2. Retail Pharmacies
9.2.3. Online Pharmacies
9.3. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.3.1. Germany
9.3.2. UK
9.3.3. France
9.3.4. Spain
9.3.5. Italy
9.3.6. Rest of Europe
9.4. Europe Condyloma Market – Opportunity Analysis Index, By Treatment, By End User, and Country, 2022 – 2028
9.5. Europe Condyloma Market Dynamics – Trends
10. Asia-Pacific Condyloma Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
10.1. Treatment Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Prescription Drugs
10.1.1.1. Imiquimod
10.1.1.2. Podophyllin and Podofilox
10.1.1.3. Trichloroacetic Acid
10.1.1.4. Sinecatechins
10.1.1.5. Others
10.1.2. Surgery
10.1.2.1. Cryotherapy
10.1.2.2. Electrocautery
10.1.2.3. Surgical Excision
10.1.2.4. Laser Treatments
10.1.2.5. Others
10.2. End User Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.2.1. Hospitals
10.2.2. Retail Pharmacies
10.2.3. Online Pharmacies
10.3. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.3.1. China
10.3.2. India
10.3.3. Japan
10.3.4. ASEAN
10.3.5. Australia & New Zealand
10.3.6. Rest of Asia-Pacific
10.4. Asia-Pacific Condyloma Market – Opportunity Analysis Index, By Treatment, By End User, and Country, 2022 – 2028
10.5. Asia-Pacific Condyloma Market Dynamics – Trends
11. Latin America Condyloma Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
11.1. Treatment Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Prescription Drugs
11.1.1.1. Imiquimod
11.1.1.2. Podophyllin and Podofilox
11.1.1.3. Trichloroacetic Acid
11.1.1.4. Sinecatechins
11.1.1.5. Others
11.1.2. Surgery
11.1.2.1. Cryotherapy
11.1.2.2. Electrocautery
11.1.2.3. Surgical Excision
11.1.2.4. Laser Treatments
11.1.2.5. Others
11.2. End User Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.2.1. Hospitals
11.2.2. Retail Pharmacies
11.2.3. Online Pharmacies
11.3. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
11.3.1. Brazil
11.3.2. Mexico
11.3.3. Argentina
11.3.4. Rest of Latin America
11.4. Latin America Condyloma Market – Opportunity Analysis Index, By Treatment, By End User, and Country, 2022 – 2028
11.5. Latin America Condyloma Market Dynamics – Trends
12. Middle East and Africa Condyloma Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
12.1. Treatment Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Prescription Drugs
12.1.1.1. Imiquimod
12.1.1.2. Podophyllin and Podofilox
12.1.1.3. Trichloroacetic Acid
12.1.1.4. Sinecatechins
12.1.1.5. Others
12.1.2. Surgery
12.1.2.1. Cryotherapy
12.1.2.2. Electrocautery
12.1.2.3. Surgical Excision
12.1.2.4. Laser Treatments
12.1.2.5. Others
12.2. End User Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.2.1. Hospitals
12.2.2. Retail Pharmacies
12.2.3. Online Pharmacies
12.3. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
12.3.1. Gulf Cooperation Council (GCC) Countries
12.3.2. Israel
12.3.3. South Africa
12.3.4. Rest of MEA
12.4. MEA Condyloma Market – Opportunity Analysis Index, By Treatment, By End User, and Country, 2022 – 2028
12.5. MEA Condyloma Market Dynamics – Trends
13. Competition Landscape
13.1. Strategic Dashboard of Top Market Players
13.2. Company Profiles (Introduction, Financial Analysis, Offerings, Key Developments, Strategies, and SWOT Analysis)
13.2.1. Bausch Health Companies Inc.
13.2.2. Graceway Pharmaceuticals
13.2.3. Glenmark
13.2.4. Allergan
13.2.5. Teva Pharmaceutical Industries Ltd.
13.2.6. Perrigo Company plc
13.2.7. Novartis AG
13.2.8. Merck & Co. Inc.
13.2.9. Emblation Ltd.
13.2.10. Verrica Pharmaceuticals
13.2.11. Novan, Inc.
13.2.12. GlaxoSmithKline plc.
13.2.13. Pfizer Inc.
13.2.14. Mylan N.V.
13.2.15. Taro Pharmaceutical Industries Ltd.
13.2.16. Cipla Ltd.
13.2.17. Phio Pharmaceuticals Corp.
13.2.18. Prestige Consumer Healthcare Inc.
13.2.19. AIM ImmunoTech, Inc.
14. Research Methodology
15. Key Assumptions and Acronyms

Report

Company Profile

  • Bausch Health Companies Inc.
  • Graceway Pharmaceuticals
  • Glenmark
  • Allergan
  • Teva Pharmaceutical Industries Ltd.
  • Perrigo Company plc
  • Novartis AG
  • Merck & Co. Inc.
  • Emblation Ltd.
  • Verrica Pharmaceuticals
  • Novan, Inc.
  • GlaxoSmithKline plc.
  • Pfizer Inc.
  • Mylan N.V.
  • Taro Pharmaceutical Industries Ltd.
  • Cipla Ltd.
  • Phio Pharmaceuticals Corp.
  • Prestige Consumer Healthcare Inc.
  • AIM ImmunoTech, Inc.

Description

Condyloma Market Size was valued at USD 1,739.6 Million in 2021 and is poised to grow at a significant CAGR of 5.1% over the forecast period of 2022-2028. Anogenital warts spurred on by the human papillomavirus (HPV) are referred to as condyloma acuminate and can affect both the male and female populations. Anogenital warts are most frequently carried on by HPV strains 6 and 11. Warts can develop anywhere near the vagina, cervix (in females), and scrotum, penis, groin, or thighs (in males). A double-stranded DNA virus called HPV is typically transmitted through intercourse. Condyloma acuminata susceptibility is influenced by one’s age, way of life, and sexual habits. Topical treatments include imiquimod cream, sinecatechins ointment, and solutions and creams containing podophyllotoxin. Other viable therapies include cryotherapy, trichloroacetic acid solution, and several surgical techniques. Following topical therapies, Condyloma acuminata has a possibility of returning. The only therapy with clearance rates close to 100% is surgical excision. Patients should be given advice on available treatments, the value of follow-up visits, and safe sex procedures. With 9 to 13 percent of the world’s population afflicted, HPV is the most prevalent sexually transmitted illness. Most often, patients between the ages of 20 and 39 are impacted. Thus, with high prevalence, primarily in the young generation, the condyloma treatment market is predicted to grow in the presumption period. There are several identified risk factors for HPV infection. The likelihood of contracting an infection rises with more past sexual partners, a history of gonorrhea and chlamydia infections, smoking, and HIV infection. With around 10 million cigarettes sold worldwide and 36.9 million people living with HIV (including 1.8 million children), the chances of condyloma morbidity are to increase in the future, thus giving the thrust for the condyloma market growth. The occurrence of condyloma acuminata is challenging to predict since anogenital warts are not a disease that must be reported. However, according to current estimates, there are 1.1 to 1.2 incidences of anogenital warts per 1000 people per year in the United States. Further, there are international level efforts by the World Health Organization to educate the population through an authoritarian level awareness campaign and eliminate sexually transmitted diseases by providing health care facilities and funds to the governments worldwide, which will drive the condyloma treatment market to flourish in the prognosticate span of the report. The major restrain for the condyloma market is the nonreporting of the disease. The disease prevalence is much higher than reported as this disease is typically nonlethal many infected patients never report it.

Key Developments:

March 2021, Verrica signed a License Agreement with Torii Pharmaceutical Co. Ltd. granting Torii an exclusive license to develop and commercialize Verrica’s product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102.

In October 2018, Novan entered partnership with Health Decisions, a specialist Contract Research Organization (CRO), and announced clinical trial Phase II data for the treatment of external genital warts (EGW).

ASIA PACIFIC OFFICE

Precision Business Insights, MIG 366, SAI PLAZA, 1st Floor, KPHB Colony, Hyderabad - 500072

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX